Abnormal activation of amino acid kinases or gain-of-function mutations, mainly in RAS or RAF genes, lead to alterations in the RAS-RAF-MEK-ERK-MAPK (RAS-MAPK) pathway in human cancers [24]. This evidence concerns the gene RAF1 and cancer.